Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
Abstract Background Age-related macular degeneration (AMD) is a common and chronic eye condition characterized by the presence of progressive degenerative abnormalities in the central retina (macula). Notably, neovascular, or wet, AMD (nAMD) occurs when new, abnormal blood vessels grow under the mac...
Saved in:
Main Authors: | Nicola Ferrante (Author), Daniela Ritrovato (Author), Rossella Bitonti (Author), Gianluca Furneri (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis
by: Junlan Chuan, et al.
Published: (2022) -
First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022) -
Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age‐related macular degeneration
by: Nadia Zakaria, et al.
Published: (2022) -
The Short-term efficacy of a monoclonal antibody fragment (brolucizumab) for treating neovascular age-related macular degeneration
by: A. F. Yusupov, et al.
Published: (2024) -
A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result
by: Wataru Kikushima, et al.
Published: (2023)